Historical Valuation
Iterum Therapeutics PLC (ITRM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.68 is considered Undervalued compared with the five-year average of -2.12. The fair price of Iterum Therapeutics PLC (ITRM) is between 9.58 to 9.92 according to relative valuation methord. Compared to the current price of 0.33 USD , Iterum Therapeutics PLC is Undervalued By 96.58%.
Relative Value
Fair Zone
9.58-9.92
Current Price：0.33
96.58%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Iterum Therapeutics PLC (ITRM) has a current Price-to-Book (P/B) ratio of -2.09. Compared to its 3-year average P/B ratio of -3.07 , the current P/B ratio is approximately -31.98% higher. Relative to its 5-year average P/B ratio of -1.03, the current P/B ratio is about 101.72% higher. Iterum Therapeutics PLC (ITRM) has a Forward Free Cash Flow (FCF) yield of approximately -117.63%. Compared to its 3-year average FCF yield of -136.63%, the current FCF yield is approximately -13.91% lower. Relative to its 5-year average FCF yield of -97.21% , the current FCF yield is about 21.00% lower.
P/B
Median3y
-3.07
Median5y
-1.03
FCF Yield
Median3y
-136.63
Median5y
-97.21
Competitors Valuation Multiple
AI Analysis for ITRM
The average P/S ratio for ITRM competitors is 331.34, providing a benchmark for relative valuation. Iterum Therapeutics PLC Corp (ITRM.O) exhibits a P/S ratio of 2.68, which is -99.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ITRM
1Y
3Y
5Y
Market capitalization of ITRM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ITRM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ITRM currently overvalued or undervalued?
Iterum Therapeutics PLC (ITRM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.68 is considered Undervalued compared with the five-year average of -2.12. The fair price of Iterum Therapeutics PLC (ITRM) is between 9.58 to 9.92 according to relative valuation methord. Compared to the current price of 0.33 USD , Iterum Therapeutics PLC is Undervalued By 96.58% .
What is Iterum Therapeutics PLC (ITRM) fair value?
ITRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Iterum Therapeutics PLC (ITRM) is between 9.58 to 9.92 according to relative valuation methord.
How does ITRM's valuation metrics compare to the industry average?
The average P/S ratio for ITRM's competitors is 331.34, providing a benchmark for relative valuation. Iterum Therapeutics PLC Corp (ITRM) exhibits a P/S ratio of 2.68, which is -99.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Iterum Therapeutics PLC (ITRM) as of Jan 10 2026?
As of Jan 10 2026, Iterum Therapeutics PLC (ITRM) has a P/B ratio of -2.09. This indicates that the market values ITRM at -2.09 times its book value.
What is the current FCF Yield for Iterum Therapeutics PLC (ITRM) as of Jan 10 2026?
As of Jan 10 2026, Iterum Therapeutics PLC (ITRM) has a FCF Yield of -117.63%. This means that for every dollar of Iterum Therapeutics PLC’s market capitalization, the company generates -117.63 cents in free cash flow.
What is the current Forward P/E ratio for Iterum Therapeutics PLC (ITRM) as of Jan 10 2026?
As of Jan 10 2026, Iterum Therapeutics PLC (ITRM) has a Forward P/E ratio of -0.72. This means the market is willing to pay $-0.72 for every dollar of Iterum Therapeutics PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Iterum Therapeutics PLC (ITRM) as of Jan 10 2026?
As of Jan 10 2026, Iterum Therapeutics PLC (ITRM) has a Forward P/S ratio of 2.68. This means the market is valuing ITRM at $2.68 for every dollar of expected revenue over the next 12 months.